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background:  Large clinical trials demonstrated the benefit of statin therapy in both patients with acute coronary syndrome (ACS) and 
stable angina pectoris (SAP). However, the vascular response to statin therapy in relation to the clinical presentation is largely unknown.
methods:  Sixty-nine patients (55 ACS, 14 SAP) from a prospective, randomized trial (NCT01023607) were included. Each patient 
underwent optical coherence tomography and intravascular ultrasound at baseline, 6 months, and 12 months. Non-culprit plaque features 
were compared between ACS and SAP groups.
Results:  A total of 97 plaques were analyzed (ACS, n=74; SAP, n=23). Fibrous cap thickness (FCT) steadily increased in both ACS and 
SAP patients (all p<0.001) (Figure). However, the absolute increase in FCT after 12 months was significantly greater in patients with ACS 
than in those with SAP (108.8 ± 76.0 μm vs. 79.4 ± 63.5 μm; p=0.047). Patients with ACS showed decrease in macrophage accumulation 
(70.3% [baseline] vs. 52.8% [12 months]; p=0.030); however, this was not observed in patients with SAP (p=0.945). In addition, prevalence 
of neovascularization significantly decreased only in patients with ACS (44.6% [baseline] vs. 26.6% [12 months]; p=0.028). No changes in 
percent atheroma volume were noted in both groups.
conclusion:  Patients with ACS showed a more favorable vascular response to statin therapy than those with SAP, including greater FCT 
increase, and decrease in plaque inflammation and neovascularization.
 
